Mucosal Adjuvant Boosts Immunity Against Genital Herpes
Publication Title: Bioactive enhanced adjuvant chemokine oligonucleotide nanoparticles (BEACONs) for mucosal vaccination against genital herpes.
Summary
- Question
- This study aimed to address the lack of an effective vaccine for genital herpes caused by herpes simplex virus type 2 (HSV-2). The researchers developed bioactive enhanced adjuvant chemokine oligonucleotide nanoparticles (BEACONs), which combine CpG oligodeoxynucleotides (short DNA sequences that stimulate the immune system) with the chemokine CXCL9. They tested whether this novel mucosal adjuvant, when combined with HSV-2 glycoproteins, could improve localized immunity in the vaginal mucosa and provide better protection against HSV-2 infection.
- Why it Matters
- Genital herpes affects millions globally, with no vaccine currently available. Existing antiviral treatments manage symptoms but do not prevent infection or reactivation. HSV-2 infection also increases the risk of acquiring other sexually transmitted infections, such as HIV. Effective mucosal immunity at the site of viral entry is critical but difficult to achieve with traditional vaccine methods. This study is significant because it explores a novel approach to eliciting strong localized immune responses, which could lead to better vaccines for HSV-2 and other sexually transmitted infections.
- Methods
- The researchers used a 'prime and boost' vaccination strategy in mice. First, they primed the immune system with an intramuscular injection of mRNA lipid nanoparticles encoding HSV-2 glycoproteins. Then, they delivered a mucosal boost intravaginally using recombinant glycoproteins combined with BEACONs. The study measured immune responses, viral load, and survival following HSV-2 challenge.
- Key Findings
- The combination of BEACONs and HSV-2 glycoproteins significantly enhanced immune responses in the vaginal mucosa. This approach increased the presence of tissue-resident memory T cells (a type of immune cell that remains in tissues to provide localized protection) and mucosal antibodies, both of which are crucial for controlling HSV-2 infection. Mice that received this vaccine regimen showed reduced disease severity, lower viral loads, and improved survival compared to those receiving traditional intramuscular boosts.
- Implications
- This research highlights the potential of using BEACONs as a mucosal vaccine adjuvant to overcome the limitations of traditional vaccination methods. By enhancing local immune defenses at the site of viral entry, this approach could lead to more effective vaccines for HSV-2 and other infections requiring mucosal immunity, such as HIV or human papillomavirus. Additionally, the findings emphasize the importance of combining systemic and localized vaccination strategies.
- Next Steps
- Future research should explore the long-term durability of the immune responses induced by BEACONs, as well as their efficacy in models that mimic human physiology more closely, such as hormonal cycling and diverse microbiota. Studies are also needed to develop clinically viable formulations, such as slow-release platforms or self-administered vaccine delivery systems.
- Funding Information
- This research was supported by a grant from the Howard Hughes Medical Institute to Akiko Iwasaki. Yale University also provided funding and support for this research.
Full Citation
Bhagchandani SH, Ehrenzeller S, Pires IS, Chaudhary N, Booth CJ, Kwon DI, Koutsioumpa C, Baker CA, Laxton C, Santos Guedes de Sá K, Matthews C, Gill P, Li S, Olszowka A, Hudak A, Fischer S, Bayarri-Olmos R, Hooper WB, Iwasaki A. Bioactive enhanced adjuvant chemokine oligonucleotide nanoparticles (BEACONs) for mucosal vaccination against genital herpes. Sci Immunol 2026, 11: eaea6419. PMID: 42319912, DOI: 10.1126/sciimmunol.aea6419.
This AI-assisted summary has been reviewed and approved by at least one of the study's authors to ensure it accurately reflects the research.
Authors
Sachin Haresh Bhagchandani
First AuthorPostdoctoral Associate
Akiko Iwasaki, PhD
Last AuthorSterling Professor of Immunobiology and Professor of Dermatology and of Molecular, Cellular, and Developmental Biology and of Epidemiology (Microbial Diseases)